Previous Close | 2.0000 |
Open | 2.0200 |
Bid | 1.5000 x 1000 |
Ask | 2.2000 x 800 |
Day's Range | 1.9300 - 2.2100 |
52 Week Range | 1.8200 - 11.1000 |
Volume | |
Avg. Volume | 172,539 |
Market Cap | 134.815M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.3200 |
Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 16.25 |
Subscribe to Yahoo Finance Plus to view Fair Value for PSTX
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of Charles M. Baum, M.D., Ph.D., to its Board of Directors, effective May 16, 2022. Additionally, the Company announced the resignation of David Hirsch, M.D., Ph.D., from its Board of Directors, effective May 17, 2022.
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today will present preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 2022 Annual Meeting highlighting the use of anti-c-kit CAR-T cells as a preconditioning agent to enable hematopoietic stem cell (HSC) transplants. The ASGCT Annual Meeting is being held in Wash
There's been a notable change in appetite for Poseida Therapeutics, Inc. ( NASDAQ:PSTX ) shares in the week since its...